In fact, bevacizumab was shown to upregulate ANGPT2, and blockade of both VEGF and ANGPT2 extended survival, decreased vascular permeability by potentially reducing vasogenic cerebral edema, and favored antitumor immunity by enhancing tumor infiltrating lymphocytes and decreasing tumor-associated macrophages (30). This evidence concerns the gene ANGPT2 and edema.